Add BrightSurf on Google Email

Science News for February 22, 1999


Ablatherm: An Ultrasound Device For Prostate Cancer Therapy

The Ablatherm device has shown local disease control in approximately 80% of cases, with a complete response in 56% and partial response in 24%. The treatment is minimally invasive and can be repeated if necessary, but may have some adverse effects.

SourceFrench National Institute for Health and Medical Research (INSERM)·DateFeb 22, 1999
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Chelation Therapy May Alter Immune System

A Cornell University study suggests that chelation therapy used to treat lead poisoning in children may have adverse effects on the developing immune system. The therapy, DMSA, was found to impair immune function in offspring of pregnant rats who received the treatment during pregnancy.

SourceCornell University·JournalToxicology·DateFeb 22, 1999

It's All In The Mind... Brain Mapping Of Sexual Arousal

Researchers identified five brain areas activated during sexual arousal, including the inferior temporal cortex and right orbitofrontal cortex. The study used positron emission tomography to map brain activity while subjects watched different films, providing insights into the neurophysiological bases of human sexuality.

SourceFrench National Institute for Health and Medical Research (INSERM)·JournalArchives of Sexual Behavior·DateFeb 22, 1999

Women Who Have Invasive Cervical Cancer Benefit From Addition Of Chemotherapy To Radiation Treatment

A landmark study involving women with invasive cervical cancer showed that adding chemotherapy to radiation therapy significantly improves survival rates and disease-free survival. The study found that 73% of patients who received both treatments survived for at least five years, compared to 58% of those given only radiation.

SourceWashU Medicine·JournalNew England Journal of Medicine·DateFeb 22, 1999